Category: Biosimilars

Biosimilars: Who wants to play this game? 
Posted on Apr 14, 2017

     A recent post by Robert Wessman of Alvogen pointed out that some companies are abandoning their efforts in the biosimilars markets. Amgen, for instance, recently decided to postpone the launch of a biosimilar version of adalimumab until litigation issues are resolved, which could take years (if ever). By the way, adalimumab is a

Looking Backward, Looking Forward 
Posted on Jan 03, 2017

  I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake, alt right, safe spaces, and so on.    While peace was finally achieved in the Western Hemisphere (Colombia), it is escalating in the Middle East

The $25 Coffee Mug 
Posted on Sep 30, 2016

Our recent trip to Stockholm and the Nordic Life Science Days conference was quite enlightening, especially as we publicly discuss drug prices (yet again).  One presentation at NLSD by SwedenBio enlightened us on how a different system and society views drug pricing. From the Swedish socialist perspective, one of their aims (aside from job creation) is to provide their citizens

Injectables: Will They Become As Common As Orals? 
Posted on Apr 26, 2016

Our friends at PharmaCircle recently published an interesting and provocative piece entitled Injectables: The New Oral? The PDF is available here. The article notes that, in 2014, seven of the top ten pharmaceuticals were parenteral products, with products such as Humira, Remicade, and Enbrel achieving $9-12+ billion in sales. This is a huge change from

White Paper: Six Considerations When Developing a Biosimilar Strategy 
Posted on Sep 11, 2014

  Thompson Reuters published a good overview of the challenges facing companies developing biosimilars. A few items which stood out for us were: Europe Has Led, But… – While 17 biosimilars have been launched in Europe, the path has been slow and uncertain. Pricing for biosimilars remains high, and issues such as product naming and

Biogeneric infliximab now available in Europe 
Posted on Sep 10, 2013

    Today we learn that a biogeneric form of Remicade, the first biogeneric monoclonal antibody, will shortly be available in Europe: Tuesday’s final green light for Inflectra – which was developed by South Korea’s Celltrion and will be marketed by U.S. company Hospira – had been expected following a European Medicines Agency recommendation in

Biocon Mylan Biogenerics Partnership 
Posted on Feb 14, 2013

Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars: Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus®), Lispro (the generic version of Eli Lilly’s Humalog®) and Aspart (the

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.